deaths (OS)

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1 certainty unassessable-11%
ipilimumab alone vs. interferon alpha 1 low degree of certaintystatistically conclusive-16%
versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 certainty unassessable-12%
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1 certainty unassessablestatistically conclusive-26%
nivolumab alone vs. placebo 1 -
nivolumab plus ipilimumab vs. placebo 1 -
pembrolizumab alone vs. placebo 1 -